Glaucoma treatment
AssigneesChildren's Medical Center Corporation, Massachusetts Eye and Ear Infirmary
InventorsStuart A. Lipton, Evan B. Dreyer
Life of this patent
Estimating the term…
Abstract
Elevated glutamate levels are associated with glaucoma, and damage to retinal ganglion cells can be controlled by administering to the patient a compound capable of reducing glutamate induced excitotoxicity in a concentration effective to cause reduction of such excitotoxicity.
Claims16
A method of protecting against retinal damage in a human glaucoma patient, said method comprising administering to said patient a compound that is an uncompetitive antagonist of the NMDA receptor-channel complex in an amount effective to effect such protection, wherein said compound is an adamantane derivative.
A method of protecting a human patient from damage to retinal ganglion cells associated with non-vascular forms of glaucoma, said method comprising systemically or intravitreally administrating to said patient a compound that is an antagonist of glutamate induced excitotoxicity, in a concentration effective to cause reduction of said excitotoxicity, said antagonist being an antagonist of NMDA receptor-mediated neurotoxicity, wherein said compound is an adamantane derivative.
A method of treating glaucoma in a human patient by administering to the retinal ganglion cells of a glaucoma patient a composition comprising an effective amount of an amantadine derivative that is an antagonist of NMDA receptor mediated neuronal toxicity.
A method of treating glaucoma in a human patient by administering to the retinal ganglion cells of a glaucoma patient a composition comprising an effective amount of an compound selected from amantadine, rimantadine, and memantine.
Dependencies are inferred from the claim text.